India starts probe against 4 cough syrups after WHO alerts its adverse effects on kids

New Delhi : India has started an investigation against four cough syrups manufactured by a Haryana-based pharmaceutical firm a day after WHO alerted that they can be a reason behind the death of 61 children in the Gambia.

According to a media report, WHO had informed the DGCI about the cough syrup on September 29, 2022, after which DGCI immediately took up the matter with Haryana regulatory authorities and asked for a detailed investigation report in the matter.

It has been learned that the cough syrups were made by the Maiden Pharmaceutical Limited in Haryana's Sonepat. The company had exported the cough syrups only to The Gambia.

Meanwhile, WHO has issued a warning that the cough syrups may have been distributed outside and may cause global exposure.

Meanwhile, WHO is yet to provide the data mentioning the exact time and location of the deaths caused by an alleged consumption of the syrups.

The samples of the cough syrups will be tested in Indian laboratories and the results will be given in two-three days.